Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Scheller

Showing results (291-300 of 295) with videos related to

Pageof 30
Sort By:
You have reached the last page of results.This site can display upto 295 results.
Molecular Cancer Therapeutics|December 29, 2017
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Molecular Cancer Therapeutics|November 3, 2019
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Nature Biotechnology|July 22, 2008
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R Junutula, Helga Raab, Suzanna Clark, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Pageof 30

Showing results (291-300 of 295) with videos related to

Sort By:
Pageof 30
You have reached the last page of results.This site can display upto 295 results.
Molecular Cancer Therapeutics|December 29, 2017
An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Molecular Cancer Therapeutics|November 3, 2019
Correction: An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast CancerSunil Bhakta, Lisa M Crocker, Yvonne Chen, et al.
Journal of Medicinal Chemistry|September 6, 2014
Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringThomas H Pillow, Janet Tien, Kathryn L Parsons-Reponte, et al.
Nature Biotechnology|July 22, 2008
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexJagath R Junutula, Helga Raab, Suzanna Clark, et al.
Nature Biotechnology|January 24, 2012
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen-Quan Shen, Keyang Xu, Luna Liu, et al.
Pageof 30